• Explore /
  • Poster
  • / MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.

MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.

Abstract Poster

Authors

William Tap

William D. Tap

Memorial Sloan Kettering Cancer Center, New York, NY

William D. Tap , Andrew J. Wagner , Maitreyi G. Sharma , Marc Vallee , Mary F. Michenzie , Matthew L. Sherman , Rodrigo Ruiz-Soto , Silvia Stacchiotti , Michiel A.J. van de Sande , Hans Gelderblom

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT05059262

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS11590)

DOI

10.1200/JCO.2022.40.16_suppl.TPS11590

Abstract #

TPS11590

Poster Bd #

490a

Abstract Disclosures

Similar Posters

First Author: Hans Gelderblom

First Author: Guillaume Canaud

First Author: Andrew Peter Dean

First Author: Gang Jin